Skip to main content
Novel antidepressant shines in phase 2 trial, but FDA has issues with its NDA
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Novel antidepressant shines in phase 2 trial, but FDA has issues with its NDA
User login
Username
Password
Reset your password
Concept
Lead
score
Depression
1
1
Food and Drug Administration (FDA)
0
0.95
Antidepressant drug
0
0.47
Agitation
0
0.16
Bacteremia
0
0.16
Grant
0
0.16
Major Depression
0
0.16
Remission
0
0.16
Gout
0
0.11
Sepsis
0
0.11
Specialty
Lead
score
Psychiatry
1
1
Family Medicine/Primary Care
0
0.9
Internal Medicine
0
0.8
Neurology & Neurosurgery
0
0.7